Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Bloom Gone From Rosy ANDA Approvals Figures?

Executive Summary

US FDA sets a new monthly record for full approvals, but industry group argues that approvals alone aren't creating more generic competition in the market.

You may also be interested in...



FDA Reports Millions In Unpaid GDUFA Fees

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

US FDA Reports Millions In Unpaid GDUFA Program Fees

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

Generic Industry Wants US FDA To Consider Allowing Foreign Reference Products For ANDAs

If agency adopts policy, it might obviate the need for the CREATES Act. Biosimilars already enjoy a degree flexibility of on the source of reference material that generic sponsors want extended to the less complicated small molecule drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS124242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel